Navigation Links
How 'IAP antagonist' chemicals kill tumors
Date:11/15/2007

Chemical compounds specially designed to neutralize proteins that would otherwise allow tumor cells to cheat death have been recognized for some time by scientists as a promising new avenue for cancer therapy. Now, two studies in the November 16, 2007 issue of the journal Cell, a publication of Cell Press, provide insight into just how these antagonists of the anti-deathso-called Inhibitor-of-Apoptosis (IAP)proteins work to fight tumors.

The researchers reveal that the compounds hit specific IAP proteins known as cIAPs. That came as a surprise, they said, because the chemicals had originally been designed to target another of the anti-death proteins. The studies further show that the small molecule inhibitors not only block the death-defying proteins, but they also actively engage other players that lead to the death of tumor cells. Meanwhile, the chemicals seem to have little effect on healthy cells.

There has been an effort for several years to look for IAP antagonists, which seem to be very good in causing cell death in cancer, said Domagoj Vucic of Genentech, Inc. in South San Francisco, who led one of the two studies. It was thought they might be used in combination with other drugs. But now, we show that these chemicals are capable of inducing apoptosis all on their own.

It appears that when you remove cIAP1 in sensitive cancer cells, it opens the tap and everything just goes [toward cell death], added John Silke of La Trobe University in Australia, who led the other study. cIAP1 seems to be critical in deciding the life-or-death balance.

Apoptosis or programmed cell death is a cell suicide mechanism with a major role in development and homeostasis in all animals, Vucic explained. It is now accepted that apoptosis is also an extremely important defense against tumors, Silke added.

Scientists initially discovered the IAP proteins capable of blocking cell death in, of all things, a caterpillar virus, Silke said. The IAP proteins were later found in other organisms, from flies to mammals. The proteins were also shown to rise in human cancer, making them attractive targets for the development of novel cancer therapeutics. Scientists have therefore sought to design molecules that could antagonize IAPs, taking the lead from natural IAP antagonists.

Vucics group now shows that an IAP antagonist leads cIAPs to be marked for degradation by cellular components known as proteosomes. This is an amazingly rapid occurrence, happening within two minutes in cells in culture after exposure to the compound, said Vishva Dixit, who is also from Genentech.

They found that treatment with the IAP antagonist led to the activation of a NF-"B pathway that produces another protein, called tumor necrosis factor (TNFa). TNFa comes back and binds its receptor, triggering unimpeded apoptosis and killing cancer cells, Vucic said.

Likewise, Silkes team showed that synthetic and naturally occurring IAP antagonists kill susceptible tumor cells through their action on cIAP1, resulting in NF-"B activation, which drives TNFa production and initiates tumor cell death. Silke noted that the congruence between the findings of the two studies is a really good sign.

These studies show the potential for these drugs, although there is a long road to go, Silke added. It also demonstrates an important principle: If you can understand how something works through basic scientific discoveries, then you can really start to make targeted tumor therapies. We can begin to understand how tumors live and how to make them die.

Vucic said that a phase I clinical trial designed to test the safety of one of their IAP antagonist compounds in human patients is already underway.


'/>"/>

Contact: Cathleen Genova
cgenova@cell.com
617-397-2802
Cell Press
Source:Eurekalert

Related medicine news :

1. Rohm and Haas to Webcast Presentation at Credit Suisse Chemicals Conference
2. National Academies advisory: genes and toxic chemicals
3. Genomic technologies to identify toxic chemicals should be developed
4. Researchers study potential health benefits of natural chemicals in muscadine grape seeds
5. Study reveals huffing household chemicals connected to teen suicide
6. Marijuana-like brain chemicals work as antidepressant
7. Hazardous Advanced Micro Devices (A.M.D.) Clean Room Chemicals Caused Multiple Birth Defects, Lawsuit Alleges
8. Tumors use enzyme to recruit regulatory T-cells and suppress immune response
9. Study suggests brain tumors need treatment with multiple targeted drugs
10. Bright tumors, dim prospects
11. Genomic profiling of lung tumors helps doctors choose most effective treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the ... advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, ... Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up with ...
(Date:12/8/2016)... ... ... Fitness Camp (PFC) and The Chopra Center for Wellbeing announced today the launch of ... headquarters of Omni La Costa Resort & Spa in San Diego. , Chopra FIT ... development, a healthy lifestyle, or mental and physical healing. The week-long wellness program combines ...
(Date:12/8/2016)... N.J. (PRWEB) , ... December 08, 2016 , ... ... delivery technologies and development solutions for drugs, biologics and consumer health products, today ... PSCI was set up in 2006 as a non-profit organization to unite pharmaceutical ...
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... Vida ... raised an $18M Series B led by Canvas Ventures . Other investors include ... to scale its mobile platform to serve more consumers who are managing chronic ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... -- Information products and services provider Elsevier ... , the world,s largest abstract and citation database of peer-reviewed literature, ... from over 5,000 publishers. The new set of metrics will improve ... when to adjust a journal,s editorial strategy. ... , , CiteScore ...
(Date:12/8/2016)... 8, 2016 According to the research ... Market is expected to be worth US$9.7 bn by ... 2015. Between the forecast years of 2016 and 2024, the ... 7.9%. The leading players operating in the global diabetes injection ... AstraZaneca plc., Biocon Ltd., and Sanofi S.A. Transparency Market Research ...
(Date:12/8/2016)... According to a new market research report "Wearable Medical Devices Market ... Use (Sports, Fitness, RPM), Type (Smart watch, Patch), Distribution Channel (Pharmacy, Hypermarket) ... of value, is projected to reach 12.14 Billion by 2021 from USD ... period. Continue Reading ... ...
Breaking Medicine Technology: